Merkel Cell Carcinoma - Pipeline Review, H1 2017

Market: Pharmaceuticals and Healthcare

Global, 257 pages report, published by Global Markets Direct

Keywords : Merkel Cell Carcinoma Therapeutic Products under Development, Key Players in Merkel Cell Carcinoma Therapeutics, Merkel Cell Carcinoma Pipeline Overview, Merkel Cell Carcinoma Pipeline, Merkel Cell Carcinoma Pipeline Assessment

Report ThumbnailJune-2017
Merkel Cell Carcinoma - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Merkel Cell Carcinoma - Pipeline Review, H1 2017, provides an overview of the Merkel Cell Carcinoma (Oncology) pipeline landscape.

Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Risk factors for Merkel cell carcinoma include age, gender, light skin color, Ultraviolet exposure and immune suppression. Symptom includes painless nodule on skin. It usually starts on areas of skin exposed to the sun (face, neck, arms, and legs). Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Merkel Cell Carcinoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Merkel Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Merkel Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Merkel Cell Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 9, 9 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Merkel Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Merkel Cell Carcinoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Merkel Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Merkel Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Merkel Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Merkel Cell Carcinoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Merkel Cell Carcinoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Merkel Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Merkel Cell Carcinoma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
  • List of Tables
  • Number of Products under Development for Merkel Cell Carcinoma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Merkel Cell Carcinoma - Pipeline by Amgen Inc, H1 2017
  • Merkel Cell Carcinoma - Pipeline by Apcure SAS, H1 2017
  • Merkel Cell Carcinoma - Pipeline by BeiGene (Beijing) Co Ltd, H1 2017
  • Merkel Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Merkel Cell Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Merkel Cell Carcinoma - Pipeline by Immune Design Corp, H1 2017
  • Merkel Cell Carcinoma - Pipeline by Merck & Co Inc, H1 2017
  • Merkel Cell Carcinoma - Pipeline by Merck KGaA, H1 2017
  • Merkel Cell Carcinoma - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
  • Merkel Cell Carcinoma - Pipeline by NantKwest Inc, H1 2017
  • Merkel Cell Carcinoma - Pipeline by Novartis AG, H1 2017
  • Merkel Cell Carcinoma - Pipeline by OncoSec Medical Inc, H1 2017
  • Merkel Cell Carcinoma - Pipeline by Oncovir Inc, H1 2017
  • Merkel Cell Carcinoma - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
  • Merkel Cell Carcinoma - Pipeline by Philogen SpA, H1 2017
  • Merkel Cell Carcinoma - Pipeline by Tarveda Therapeutics Inc, H1 2017
  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Merkel Cell Carcinoma - Overview
  • Merkel Cell Carcinoma - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Merkel Cell Carcinoma - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Merkel Cell Carcinoma - Companies Involved in Therapeutics Development
  • Amgen Inc
  • Apcure SAS
  • BeiGene (Beijing) Co Ltd
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Immune Design Corp
  • Merck & Co Inc
  • Merck KGaA
  • Millennium Pharmaceuticals Inc
  • NantKwest Inc
  • Novartis AG
  • OncoSec Medical Inc
  • Oncovir Inc
  • Ono Pharmaceutical Co Ltd
  • Philogen SpA
  • Tarveda Therapeutics Inc
  • Merkel Cell Carcinoma - Drug Profiles
  • APC-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • atezolizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • avelumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • bevacizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BGBA-317 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellular Immunotherapy 1 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellular Immunotherapy 2 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • G-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ipilimumab + nivolumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MAL-3101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • nivolumab - Drug Profile
  • R&D Progress
  • pasireotide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pasireotide ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pazopanib hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pembrolizumab - Drug Profile
  • R&D Progress
  • PEN-221 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Poly-ICLC - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • sapanisertib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • talimogene laherparepvec - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tavokinogene telseplasmid - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Teleukin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tigilanol tiglate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target WT1 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Merkel Cell Carcinoma - Product Development Milestones
  • Featured News & Press Releases
  • May 31, 2017: Triple therapy for rare skin cancer shows promise in small, early-stage trial
  • May 17, 2017: Merck and Pfizer to Present Data Highlighting Potential of Avelumab in Challenging Cancers at ASCO 2017
  • Mar 29, 2017: BAVENCIO (avelumab) Approved for the Treatment of Metastatic Merkel Cell Carcinoma, Available for Order at Biologics
  • Mar 23, 2017: FDA Grants Approval for BAVENCIO (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
  • Mar 20, 2017: NantKwest Announces FDA Grant of Orphan Drug Designation for the Company’s aNK Natural Killer Cell Therapy in Merkel Cell Carcinoma
  • Mar 01, 2017: Bristol-Myers Squibb to Present Data That Advances Understanding of Effects of Immuno-Oncology Therapies on Cancer Biology and Patient Outcomes at AACR 2017
  • Nov 29, 2016: FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review
  • Nov 14, 2016: NantKwest Announces Achievement of End Point in Merkel Cell Carcinoma Phase II Trial With Evidence of Efficacy of Activated Natural Killer (aNK) Cells in Solid Tumors
  • Oct 31, 2016: European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
  • Sep 28, 2016: Merck to Present Data on Avelumab at ESMO 2016
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

Please select a license type

Share

Related Products

Global Markets DirectMerkel Cell Carcinoma - Pipeline Review, H1 2017Product ThumbnailMerkel Cell Carcinoma - Pipeline Review, H1 2017, Industry ReportProduct #: 829016
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved